Your browser doesn't support javascript.
loading
Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy.
Boccia, Ralph; O'Boyle, Erin; Cooper, William.
Afiliação
  • Boccia R; Center for Cancer and Blood Disorders, 6410 Rockledge Drive #660, Bethesda, MD, 20819, USA. RBoccia@CCBDMD.com.
  • O'Boyle E; FibroGen, Inc, 409 Illinois Street, San Francisco, CA, 94158, USA.
  • Cooper W; TFS, Inc, 212 Carnegie Center, Suite 208, Princeton, NJ, 08540, USA.
BMC Cancer ; 16: 166, 2016 Feb 26.
Article em En | MEDLINE | ID: mdl-26921245

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Quinuclidinas / Vômito / Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Isoquinolinas / Antieméticos / Náusea Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2016

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Quinuclidinas / Vômito / Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Isoquinolinas / Antieméticos / Náusea Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2016